Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
EML4 - ALK Alectinib pulmonary neuroendocrine tumor predicted - sensitive detail...
RET over exp Selpercatinib pulmonary neuroendocrine tumor predicted - sensitive detail...
RET over exp Pralsetinib pulmonary neuroendocrine tumor predicted - sensitive detail...
EML4 - ALK ALK I1171N Alectinib pulmonary neuroendocrine tumor predicted - resistant detail...
EML4 - ALK ALK I1171N Ceritinib pulmonary neuroendocrine tumor predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Terminated ITA | GBR | FRA | ESP 1
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT03095274 Phase II Durvalumab Tremelimumab Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) Completed ESP 0
NCT03278379 Phase II Avelumab Avelumab in G2-3 NET (NET-002) Unknown status CAN 0
NCT03278405 Phase Ib/II Avelumab Avelumab in G3 NEC (NET-001) Completed CAN 0
NCT03325816 Phase Ib/II Nivolumab Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Completed USA 0
NCT03411915 Phase I XmAb18087 A Study of XmAb18087 in Subjects With NET and GIST Completed USA 0
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Terminated USA 0
NCT03670030 Phase II Nab-rapamycin A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System Terminated USA 0
NCT03870399 Phase II Tamoxifen Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET) Completed USA 1
NCT03879694 Phase I Octreotide + Sargramostim + SurVaxM Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Recruiting USA 0
NCT04400474 Phase II Atezolizumab + Cabozantinib Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) Active, not recruiting ESP 0
NCT04427787 Phase II Cabozantinib + Lanreotide acetate A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) Unknown status ITA 0
NCT04525638 Phase II lutetium Lu 177 dotatate + Nivolumab A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours Recruiting ESP 0
NCT04538378 Phase II Durvalumab + Olaparib Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors Recruiting USA 0
NCT04665739 Phase II Everolimus lutetium Lu 177 dotatate Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Recruiting USA 0
NCT04730999 Phase II Atezolizumab + Bevacizumab + Carboplatin + Etoposide Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer (CeLEBrATE) Active, not recruiting ITA 0
NCT04893785 Phase II Cabozantinib + Temozolomide A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM) Recruiting ITA 0
NCT05557708 Phase I 212Pb-Pentixather A Safety Study of 212Pb-Pentixather Radioligand Therapy Not yet recruiting USA 0
NCT05746208 Phase II Lenvatinib + Pembrolizumab Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors Recruiting USA 0
NCT05918302 Phase III 177Lu-edotreotide Everolimus Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL) Recruiting ITA | FRA | ESP 0
NCT05997056 Phase II Nab-rapamycin Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors Recruiting USA 0